2. Search Result
Search Result
Results for "

Chemosensitivity

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

2

Biochemical Assay Reagents

5

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N1423
    Glycocholic acid
    3 Publications Verification

    		 P-glycoprotein Bcl-2 Family G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite Bacterial Apoptosis FXR Caspase MDM-2/p53 LPL Receptor Metabolic Disease Inflammation/Immunology Cancer
    Glycocholic acid is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid modulates related bile acid receptor signaling. Glycocholic acid suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA) .
    Glycocholic acid
  • HY-16657
    TAPI-1
    Maximum Cited Publications
    15 Publications Verification

    		 MMP NF-κB Apoptosis TNF Receptor Inflammation/Immunology Cancer
    TAPI-1 is a broad-spectrum MMP inhibitor and NF-κB p65 inhibitor that targets ADAM17/TACE, ADAM10 and other proteins. TAPI-1 reduces the proteolytic cleavage of membrane-bound TNF-α, decreases TNF-α levels, inhibits NF-κB pathway activation, and downregulates profibrotic markers. TAPI-1 reduces the proportion of proinflammatory immune cells, alleviates cardiac and airway fibrosis, and improves cardiac function after myocardial infarction. Meanwhile, TAPI-1 inhibits the viability, migration and invasion of esophageal squamous cell carcinoma cells, enhances the chemosensitivity of Cisplatin (HY-17394), induces apoptosis, and shows low toxicity to normal esophageal epithelial cells. TAPI-1 can be widely used in studies related to myocardial infarction-induced heart failure, severe traumatic tracheal stenosis, esophageal squamous cell carcinoma and other conditions .
    TAPI-1
  • HY-11079
    A-803467
    3 Publications Verification

    		 Sodium Channel Neurological Disease Inflammation/Immunology Cancer
    A-803467 is a potent and selective tetrodotoxin-resistant Nav1.8 sodium channel blocker (IC50=8 nM). A-803467 has shown significant anti-nociception in neuropathic and inflammatory pain models. A-803467 enhances the chemosensitivity of conventional anticancer agents through interaction with the ATP-binding cassette subfamily G member 2 (ABCG2) transporter .
    A-803467
  • HY-D0846
    Diethyl pyrocarbonate

    		Biochemical Assay Reagents Neurological Disease
    Diethyl pyrocarbonate is a potent, orally active, non-specific chemical inhibitor of RNase. Diethyl pyrocarbonate has been useful in vitro as an agent relatively specific for binding to imidazole of histidine. Diethyl pyrocarbonate inhibits central chemosensitivity in rabbits. Diethyl pyrocarbonate can modify Ser, Thr, His and Tyr residues. Diethyl pyrocarbonate can be used for modeling .
    Diethyl pyrocarbonate
  • HY-N1423A
    Glycocholic acid sodium
    3 Publications Verification

    		 P-glycoprotein Bcl-2 Family G protein-coupled Bile Acid Receptor 1 Bacterial Apoptosis FXR Caspase MDM-2/p53 LPL Receptor Endogenous Metabolite Metabolic Disease Cancer
    Glycocholic acid sodium is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid sodium inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid sodium modulates related bile acid receptor signaling. Glycocholic acid sodium suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid sodium can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA) .
    Glycocholic acid sodium
  • HY-N1423S
    Glycocholic acid-d4

    		Isotope-Labeled Compounds P-glycoprotein Bcl-2 Family G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite Bacterial Apoptosis FXR Caspase MDM-2/p53 LPL Receptor Metabolic Disease Cancer
    Glycocholic acid-d4 is the deuterium labeled Glycocholic acid (HY-N1423). Glycocholic acid is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid modulates related bile acid receptor signaling. Glycocholic acid suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA).
    Glycocholic acid-d4
  • HY-N4327
    Eurycomalactone

    		NF-κB Apoptosis Akt Bcl-2 Family Infection Inflammation/Immunology
    Eurycomalactone is an active quassinoid could be isolated from Eurycoma longifolia Jack. Eurycomalactone is a potent NF-κB inhibitor with an IC50 value of 0.5 μM. Eurycomalactone inhibits protein synthesis and depletes cyclin D1. Eurycomalactone enhances radiosensitivity through arrest cell cycle at G2/M phase and delayed DNA double-strand break repair. Eurycomalactone inhibits the activation of AKT/NF-κB signaling, induces apoptosis and enhances chemosensitivity to Cisplatin (HY-17394) .
    Eurycomalactone
  • HY-124830
    SPA70
    1 Publications Verification

    		 Others Cancer
    SPA70 is a potent and selective antagonist of human pregnane X receptor (hPXR), with an IC50 of 540 nM (Ki=390 nM). SPA70 can enhance the chemosensitivity of cancer cells .
    SPA70
  • HY-W013105
    Sodium glycocholate hydrate, 98%

    N-Cholylglycine sodium salt, 98%

    		 Bcl-2 Family Caspase Endogenous Metabolite Bacterial MDM-2/p53 P-glycoprotein LPL Receptor FXR G protein-coupled Bile Acid Receptor 1 Apoptosis Others
    Sodium glycocholate hydrate, 98% is a bile acid derivative. Sodium glycocholate hydrate, 98% downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Sodium glycocholate hydrate, 98% inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Sodium glycocholate hydrate, 98% modulates related bile acid receptor signaling. Sodium glycocholate hydrate, 98% suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Sodium glycocholate hydrate, 98% can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA) .
    Sodium glycocholate hydrate, 98%
  • HY-174346
    Skp2-IN-4

    		E1/E2/E3 Enzyme Apoptosis DNA/RNA Synthesis Cancer
    Skp2-IN-4 is an Skp2 inhibitor with a IC50 of 0.38  μM for Skp2-Cks1 binding. Skp2-IN-4 improves anti-tumor activity, inhibits the proliferation and induces S phase arrest by targeting Skp2. Skp2-IN-4 significantly enhances Cisplatin (HY-17394) chemosensitivity by suppressing the tumor cell stemness in NCl-H1299 xenograft mice model, promising for lung cancer and esophageal cancer research .
    Skp2-IN-4
  • HY-N1423B
    Glycocholic acid hydrate
    3 Publications Verification

    		 Endogenous Metabolite Caspase G protein-coupled Bile Acid Receptor 1 LPL Receptor MDM-2/p53 Bcl-2 Family P-glycoprotein FXR Bacterial Apoptosis Metabolic Disease Inflammation/Immunology Cancer
    Glycocholic acid hydrate is a bile acid derivative. Glycocholic acid hydrate downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid hydrate inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid hydrate modulates related bile acid receptor signaling. Glycocholic acid hydrate suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid hydrate can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA) .
    Glycocholic acid hydrate
  • HY-115740
    Cytarabine triphosphate

    Ara-CTP

    		 DNA/RNA Synthesis Cancer
    Cytarabine triphosphate (Ara-CTP), an active metabolite of Cytarabine, is a competitive inhibitor of DNA synthesis. Intracellular Cytarabine triphosphate levels can be used to predict chemosensitivity of leukemic blasts to Cytarabine .
    Cytarabine triphosphate
  • HY-115740A
    Cytarabine triphosphate trisodium

    Ara-CTP trisodium

    		 DNA/RNA Synthesis Cancer
    Cytarabine triphosphate (Ara-CTP) trisodiu, an active metabolite of Cytarabine, is a competitive inhibitor of DNA synthesis. Intracellular Cytarabine triphosphate trisodiu levels can be used to predict chemosensitivity of leukemic blasts to Cytarabine .
    Cytarabine triphosphate trisodium
  • HY-N1423S1
    Glycocholic acid-d5

    		Isotope-Labeled Compounds P-glycoprotein Bcl-2 Family G protein-coupled Bile Acid Receptor 1 Endogenous Metabolite Bacterial Apoptosis FXR Caspase MDM-2/p53 LPL Receptor Metabolic Disease Cancer
    Glycocholic acid-d5 is the deuterium labeled Glycocholic acid (HY-N1423). Glycocholic acid is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid modulates related bile acid receptor signaling. Glycocholic acid suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA).
    Glycocholic acid-d5
  • HY-13574
    Biricodar dicitrate

    VX 710-3

    		 P-glycoprotein Cancer
    Biricodar dicitrate (VX 710-3) is the dicitrate salt form of Biricodar (HY-13574A). Biricodar dicitrate is an inhibitor for P-glycoprotein and multidrug resistance-associated protein 1 (MRP-1), which increases the accumulation of chemotherapy drugs within cancer cells and shows effective chemosensitizing activity in multidrug resistant cells .
    Biricodar dicitrate
  • HY-N1423AR
    Glycocholic acid sodium (Standard)

    		Reference Standards P-glycoprotein Bcl-2 Family G protein-coupled Bile Acid Receptor 1 Bacterial Apoptosis FXR Caspase MDM-2/p53 LPL Receptor Endogenous Metabolite Metabolic Disease Cancer
    Glycocholic acid (sodium) (Standard) is the analytical standard of Glycocholic acid sodium (HY-N1423A). This product is intended for research and analytical applications. Glycocholic acid sodium is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid sodium inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid sodium modulates related bile acid receptor signaling. Glycocholic acid sodium suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid sodium can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA).
    Glycocholic acid sodium (Standard)
  • HY-W754548
    Glycocholic acid-13C2,d4

    		Isotope-Labeled Compounds Endogenous Metabolite P-glycoprotein Bcl-2 Family G protein-coupled Bile Acid Receptor 1 Bacterial Apoptosis FXR Caspase MDM-2/p53 LPL Receptor Metabolic Disease Cancer
    Glycocholic acid- 13C2,d4 is the deuterium labeled and 13C-labeled Glycocholic acid (HY-N1423). Glycocholic acid is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid modulates related bile acid receptor signaling. Glycocholic acid suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA).
    Glycocholic acid-13C2,d4
  • HY-115465
    Rev1-CT/RIR PPI-IN-1

    		DNA/RNA Synthesis Cancer
    Rev1-CT/RIR PPI-IN-1 (Compound 1) is a thiophene-based compound. Rev1-CT/RIR PPI-IN-1 can specifically disrupt the protein-protein interaction between Rev1-CT and RIR, with an IC50 value of 2.5 µM. Rev1-CT/RIR PPI-IN-1 can enhance chemosensitivity and reduce the mutation rate in Cisplatin (HY-17394)-sensitive HT-1080 cells. Rev1-CT/RIR PPI-IN-1 can be used for tumor research .
    Rev1-CT/RIR PPI-IN-1
  • HY-13774
    WK-X-34

    		P-glycoprotein BCRP Cancer
    WK-X-34 is a low-toxicity, highly effective multidrug resistance reversal agent. By potently inhibiting the transport functions of P-glycoprotein (P-gp, ABCB1) and breast cancer resistance protein (BCRP), WK-X-34 significantly increases the intracellular accumulation of anticancer drugs and radiotracers in drug-resistant cells. WK-X-34 exerts no significant effect on MRP transporters. WK-X-34 not only restores the chemosensitivity of multidrug-resistant ovarian cancer cells, but also significantly enhances the uptake of 99mTc-Sestamibi in P-gp-positive xenograft tumors, brain and intestinal tissues. WK-X-34 exhibits extremely low toxicity and favorable safety profiles both in vitro and in mice (at doses up to 50 mg/kg), and can be used for research on overcoming multidrug resistance in ovarian cancer .
    WK-X-34
  • HY-179535
    Axl-IN-21

    		TAM Receptor Discoidin Domain Receptor TGF-β Receptor Hedgehog Cancer
    Axl-IN-21 is an orally active and selective AXL inhibitor (Kd = 2.7 nM, IC50 = 4.0 nM). Axl-IN-21 displays kinase selectivity and retains strong activity against cancer-related mul-kinases (Mer with Kd = 1.4 nM, DDR1 with IC50 = 22.2 nM, HIPK4 with Kd = 11.0 nM and LOK with Kd =10 nM). Axl-IN-21 overcomes tumor microenvironment-driven resistance by blocking CAF-derived GAS6-induced AXL/STAT3/ABCG1 signaling, restoring chemosensitivity and inhibiting drug efflux in gastric cancer (GC). Axl-IN-21 suppresses TGF-β1-induced epithelial-mesenchymal transition (EMT), migration, and invasion in MDA-MB-231 cells. Axl-IN-21 exhibits no significant cytotoxicity in non-cancerous cells. Axl-IN-21 can be research for triple negative breast cancer and gastric cancer [1] [2] .
    Axl-IN-21

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: